Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-11
- Development stage
- Unknown
- Lead developer
- VRG Therapeutics
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Stapled Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Administration
- Intraluminal, Oral
01
Overview
IL-11 (VRG Therapeutics) is an experimental therapeutic candidate designed to inhibit the Interleukin-11 (IL-11) signaling pathway. Developed by VRG Therapeutics using their proprietary miniprotein platform, this asset targets the pro-fibrotic and pro-inflammatory activities of IL-11, a member of the IL-6 cytokine family. IL-11 has been identified as a critical mediator in the development and progression of fibrosis across multiple organs, including the lungs, liver, and heart. By antagonizing IL-11 signaling, VRG Therapeutics aims to provide a novel treatment for chronic fibrotic and inflammatory diseases where tissue scarring and persistent inflammation are primary drivers of pathology.
- Other names
- IL-11-VRG TherapeuticsIL11-VRG TherapeuticsIL 11-VRG TherapeuticsIL-11 miniprotein inhibitorIL11 miniprotein inhibitorIL 11 miniprotein inhibitor
02
Targets
IL11 (Interleukin-11)
Beyond the preview
Go deeper on IL-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-11.